Ground-breaking work by university experts in Tennessee, Texas and Swansea University is helping develop a better understanding of the growing threat posed by antifungal drug resistance.
Invasive aspergillosis is a devastating disease caused by breathing in small airborne spores of the fungus Aspergillus fumigatus and it is a condition where drug resistance has been encountered.
In a healthy person these spores are destroyed by the body's immune system but in those with a weakened immune system -- such as following organ transplantation or in someone with a lung condition such as asthma or cystic fibrosis -- they can trigger a range of problems including infections.
Every year aspergillosis leads to more than 200,000 life-threatening infections and increasingly resistance to vital antifungal drug treatments makes those infections harder to treat.
National Institutes of Health funding supported a collaboration between the University of Tennessee, the University of Texas and Swansea University as part of a $2 million, five-year research program. This support enabled investigation of resistance to the triazole class of antifungal drugs used for treating the disease
A new paper, published in the American Microbiology Society journal mBio, reveals how researchers have been able to identify a previously uncharacterised genetic mutation in clinical isolates that leads to resistance.
Professor Jarrod Fortwendel, from the University of Tennessee, said, "As with bacteria, antifungal drug resistance is a real challenge facing medicine. Understanding how the fungus becomes drug resistant is important for designing changes in therapy to overcome aspergillosis."
Professor Dave Rogers, also from the University of Tennessee, added, "It is very important that the research continues and we find out more about why it is happening and how we can tackle it for the future."
Swansea University's professor Steve Kelly, whose experience researching the field of antifungal resistance dates back to 1984, described the findings as a real breakthrough. "This paper is the result of a lot of hard work and we are delighted to now be able to publish our findings."
Source: Swansea University
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.